David Kuter, MD, DPhil, Director of Clinical Hematology at Massachusetts General Hospital, discusses recent results of a trial of mezagitamab in patients with immune thrombocytopenia (ITP).
ITP is an autoimmune bleeding disorder characterized by too few platelets in the blood. Symptoms may include bruising, nosebleed or bleeding in the mouth, bleeding into the skin, and abnormally heavy menstruation. Rarely, ITP may become a chronic ailment in adults and reappear, even after remission.
Mezagitamab is a fully human immunoglobulin IgG1 monoclonal antibody that targets and depletes CD38 expressing cells. Recent data from the phase 2 clinical trial evaluating mezagitamab was presented at the International Society on Thrombosis and Haemostasis (ISTH) 2025 Congress. Part A of the study enrolled 25 patients randomized to mezagitamab 100mg or 300mg or placebo while Part B enrolled 16 patients randomized to mezagitamab 600mg or placebo.
Results showed that through week 16 all groups experienced an increased duration of platelet response with a mean increase with mezagitamab over placebo of 4.9±1.6 weeks for 100mg, 6.9±2.1 for 300mg, and 9.6±1.7 for 600mg. Mean change from baseline in ITP patient assessment questionnaire scores illustrated a clinically meaningful improvement in health-related quality of life with mezagitamab versus placebo.
For more information, click here.
To learn more about ITP and other rare autoimmune conditions, visit https://checkrare.com/diseases/autoimmune-and-auto-inflammatory-disorders/
